CA3132780A1 - Methods of treating al amyloidosis - Google Patents

Methods of treating al amyloidosis Download PDF

Info

Publication number
CA3132780A1
CA3132780A1 CA3132780A CA3132780A CA3132780A1 CA 3132780 A1 CA3132780 A1 CA 3132780A1 CA 3132780 A CA3132780 A CA 3132780A CA 3132780 A CA3132780 A CA 3132780A CA 3132780 A1 CA3132780 A1 CA 3132780A1
Authority
CA
Canada
Prior art keywords
patient
antibody
meters
stage
amyloidosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3132780A
Other languages
English (en)
French (fr)
Inventor
Gene Kinney
Wagner Zago
Carol KARP
Radhika TRIPURANENI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prothena Biosciences Ltd
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of CA3132780A1 publication Critical patent/CA3132780A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/026—Measuring blood flow
    • A61B5/029—Measuring blood output from the heart, e.g. minute volume
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
    • A61B5/1124—Determining motor skills
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—Three-dimensional [3D] image rendering
    • G06T15/06—Ray-tracing
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—Three-dimensional [3D] image rendering
    • G06T15/50—Lighting effects
    • G06T15/506—Illumination models
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
CA3132780A 2019-03-05 2020-03-05 Methods of treating al amyloidosis Pending CA3132780A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962814252P 2019-03-05 2019-03-05
US62/814,252 2019-03-05
US201962942722P 2019-12-02 2019-12-02
US62/942,722 2019-12-02
PCT/IB2020/000186 WO2020178638A1 (en) 2019-03-05 2020-03-05 Methods of treating al amyloidosis

Publications (1)

Publication Number Publication Date
CA3132780A1 true CA3132780A1 (en) 2020-09-10

Family

ID=70476256

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3132780A Pending CA3132780A1 (en) 2019-03-05 2020-03-05 Methods of treating al amyloidosis

Country Status (17)

Country Link
US (3) US11692024B2 (https=)
EP (2) EP4582446A3 (https=)
JP (2) JP7619953B2 (https=)
KR (1) KR20220019656A (https=)
CN (1) CN113811332A (https=)
AU (1) AU2020231081A1 (https=)
BR (1) BR112021017550A2 (https=)
CA (1) CA3132780A1 (https=)
CL (1) CL2021002318A1 (https=)
FR (1) FR3111560B1 (https=)
IL (1) IL286040A (https=)
JO (1) JOP20210245A1 (https=)
MA (1) MA55209A (https=)
MX (1) MX2021010665A (https=)
PH (1) PH12021552135A1 (https=)
SG (1) SG11202109645QA (https=)
WO (1) WO2020178638A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4582446A3 (en) * 2019-03-05 2025-08-13 Prothena Biosciences Limited Methods of treating al amyloidosis
CA3192069A1 (en) * 2020-09-14 2022-03-17 Michael Spector Method of treating amyloidosis
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法
IL314229A (en) * 2022-01-11 2024-09-01 Prothena Biosciences Ltd Treatment methods for amyloidosis
AR132344A1 (es) * 2023-04-10 2025-06-18 Medimmune Llc Optimización de los dominios de unión al antígeno cd3
WO2025170969A1 (en) * 2024-02-06 2025-08-14 Prothena Biosciences Limited Methods of treating al amyloidosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
DK2237803T3 (en) 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
SMT202000031T1 (it) 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
CN107233569B (zh) 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 抗体制剂和方法
CN108771655A (zh) 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
EA201792546A1 (ru) 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
CA3004152C (en) 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
ES2914781T3 (es) 2016-06-30 2022-06-16 Prothena Biosciences Ltd Composiciones para el tratamiento de la amiloidosis
US11382974B2 (en) * 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
JP2022520572A (ja) 2019-02-12 2022-03-31 プロシーナ バイオサイエンシーズ リミテッド 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置
EP4582446A3 (en) * 2019-03-05 2025-08-13 Prothena Biosciences Limited Methods of treating al amyloidosis
TW202332465A (zh) 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Also Published As

Publication number Publication date
CN113811332A (zh) 2021-12-17
IL286040A (en) 2021-10-31
US20250188159A1 (en) 2025-06-12
MA55209A (fr) 2022-01-12
US20230331831A1 (en) 2023-10-19
PH12021552135A1 (en) 2022-08-31
SG11202109645QA (en) 2021-10-28
FR3111560B1 (fr) 2024-03-22
EP3934689A1 (en) 2022-01-12
MX2021010665A (es) 2021-12-10
BR112021017550A2 (pt) 2021-11-09
US11692024B2 (en) 2023-07-04
CL2021002318A1 (es) 2022-05-06
WO2020178638A1 (en) 2020-09-10
JP2022522889A (ja) 2022-04-20
FR3111560A1 (fr) 2021-12-24
JP2025063135A (ja) 2025-04-15
JOP20210245A1 (ar) 2023-01-30
KR20220019656A (ko) 2022-02-17
US12240894B2 (en) 2025-03-04
US20200308260A1 (en) 2020-10-01
EP3934689B1 (en) 2025-04-23
JP7619953B2 (ja) 2025-01-22
EP4582446A3 (en) 2025-08-13
EP4582446A2 (en) 2025-07-09
AU2020231081A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
US12240894B2 (en) Methods of treating AL amyloidosis
AU2018311688B2 (en) Methods and compositions for treatment of amyloid deposition diseases
CN107257806A (zh) 用于治疗pvns的抗csf1r抗体
JP2021527083A (ja) ステージｉｉｉ ｎｓｃｌｃの治療及びその治療に伴う病理学的状態の鎮静
US20250084153A1 (en) Methods of treating al amyloidosis
EP4463486A2 (en) Methods of treating al amyloidosis
US20250064794A1 (en) A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib
WO2025170969A1 (en) Methods of treating al amyloidosis
HK40066935B (en) An antibody for use in methods of treating al amyloidosis
HK40066935A (en) An antibody for use in methods of treating al amyloidosis
AU2022266821A9 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
EA048260B1 (ru) Способы лечения al-амилоидоза
US20250333509A1 (en) Methods for treating cancer, or von-hippel lindau disease using a combination of a tigit antagonist, a pd-1 antagonist, and a hif-2-alpha inhibitor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240223

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250303

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250303

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250303

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250710

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260416